Intravesical chemotherapy involves a healthcare professional injecting chemotherapy medication directly into the bladder to treat cancerous tumors. “Intravesical” means “within the bladder.” ...

In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...

A review of studies including 20,000 patients with NMIBC highlights the need for individualized NMIBC management that balances oncologic control with QoL and patient-reported outcomes. Frequent ...

The most common form of bladder cancer is transitional cell carcinoma (TCC). Non-muscle-invasive TCC is classified as stage Ta when the tumour is confined to the urothelium with no spread into the ...

INVEST: A phase Ib window of opportunity study of atezolizumab administered either intravesically or direct tumour injection in patients with bladder cancer prior to radical cystectomy. This is an ...

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, ...

Clinical utility of urine tumor DNA in bladder cancer patients. TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after ...

Nearly 200,000 Americans are living with muscle-invasive bladder cancer (MIBC)—and after decades with few major advances, newly presented data may signal a turning point in how the disease is treated.

PRINCETON, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (URGN), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty cancers, ...